Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01155518 · ClinicalTrials.gov registry record · Phase 2
Hypogonadism in Young Men With Type 2 Diabetes
A Phase 2 study, sponsored by State University of New York at Buffalo.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT01155518 is a Phase 2 study that was terminated before completion, run by State University of New York at Buffalo. The registered enrollment target is 5 participants.
The verdict
NCT01155518, a Phase 2 study, was terminated before completion, sponsored by State University of New York at Buffalo.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Low testosterone production, known clinically as hypogonadism, appears to be common complication of type 2 diabetes, affecting one in three diabetic men. Hypogonadism is known to be associated with decreased muscle mass, increased fat mass, increased inflammation and decreased fertility. In this grant, the investigators propose to study the effects of having low testosterone on 1) insulin sensitivity, the ability of the body to handle glucose 2) fat and muscle mass at specific areas of the body 3) expression of mediators of inflammation in the blood 4) semen quality. This study will compare diabetic men (with or without hypogonadism). This study will also evaluate the effect of treatment with clomiphene (a drug that increases testosterone and sperm production) or testosterone in men with diabetes and hypogonadism. The investigators hope that this project will help us understand the state of hypogonadism in young type 2 diabetic men who are in their peak fertility years and give us insights into treatment of this condition. With the rising prevalence of type 2 diabetes in the young, this project may have implications for public health.
Interventions
- DRUG placebo
- DRUG testosterone
- DRUG clomiphene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01155518
The ClinicalTrials.gov registry entry for NCT01155518 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01155518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01155518 about?
NCT01155518 is a clinical study titled "Hypogonadism in Young Men With Type 2 Diabetes". Low testosterone production, known clinically as hypogonadism, appears to be common complication of type 2 diabetes, affecting one in three diabetic men. Hypogonadism is known to be associated with decreased muscle mass, increased fat mass, increased inflammation and decreased fertility. In this gra...
What is the current status of trial NCT01155518?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2010-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01155518?
The interventions under investigation include: placebo (DRUG), testosterone (DRUG), clomiphene (DRUG).
Who is sponsoring clinical trial NCT01155518?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.